Research and Education
The Infectious Diseases Department is engaged in wide ranging research into infectious diseases and HIV infection with the goal of improving the quality of care for patients attending the Infectious Disease Service.
The research involves collaborations with colleagues worldwide, answering important clinical questions but relies on the continued active participation of patients attending the Service.
- HIV cardiac monitoring programme (HIV CMP) study
- Reverse cholesterol transport study - examining blood lipid levels in patients before and after starting antiretroviral therapy.
- Fat toxicity and lipodystrophy - the causes of lipodystrophy, one of the commonest longterm complications of antiretroviral therapy worldwide.
- Bone disease - Research into HIV and bone disease
- Tuberculosis research – SPhEAR study – has been running in the Mater Hospital for the past two years. The study examines how the body metabolises the drug rifampicin, used in the treatment of TB, and how it may be affected by use of other medications, such as those used in HIV. This research is very important as TB and HIV are both very common in the developing world.
- The Helminth Prevalence Survey – the medical literature suggests that people who have lived in countries with a high prevalence of infections of the gastrointestinal tract, may still have evidence of infection, even though they have no symptoms. The study focused on two infections, in particular schistosomiasis and strongyloides.
- The Mater Infectious Disease Cohort Project
- The HIB UPBEAT study
- The SMASH study
- The Second-line study
- NEAT 001
Abstracts and Publications in 2010
- Mallon PWG, HIV and Bone Mineral Densisty. Curr. Opin Infect. Dis. 2010, 23:1-8
- Sachell CS, el al., Platelet function and HIV: a case-control study. AIDS 2010, 24:649-657
- Mallon PWG. Bones of Contention: HIV and Bone Disease. AIDS 2010, Vienna MOSY0302
- Feeney E. et al. Peripheral Blood Mononuclear Cell Mitochondrial DNA and Mitochondrial RNA does not predict Lactic Acidosis or Symptomatic Hyperlactatemia for HIV-infected Patients on ART: A sub-group of the INITIO Trial 17th CROI; February 2010: San Francisco, Ca. Abstract 730.